2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…2018 American Transplant Congress
Belatacept-Refractory CD8+CD28–CD38hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…2018 American Transplant Congress
Glycolytic Bias in mTORC2-Deficient Dendritic Cells Potentiates Antigen-Specific Immunity and Accelerates Graft Rejection
The mechanistic target of rapamycin (mTOR) is known to function in two complexes: mTOR complex 1 (mTORC1) and mTORC2. While the function of mTORC1 in…2017 American Transplant Congress
Potential Mechanism Involving Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Composite Allotransplantation Under Combined Costimulation Blockade.
Background: Role of Regulatory T cells in vascularized composite allotransplantation (VCA) remains to be elucidated. In this study, we investigate potential mechanism involved in Tregs…2017 American Transplant Congress
Rapamycin Directly Alters Human Endothelial Cell Alloimmunogenicity.
The mTOR inhibitor rapamycin (Rapa) is known to suppress T cell function. However, many of its in vivo effects, particularly its synergistic effects with costimulation…2017 American Transplant Congress
Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.
MRC Centre for Transplantation, King's College London, London, United Kingdom
Aim“ThRIL” is a multiple site, open-label, uncontrolled, phase I clinical trial assessing the safety and applicability of a CD4+CD25+FOXP3+ regulatory T cell (Treg) immunotherapy in…2017 American Transplant Congress
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.
Department of Surgery, Duke University School of Medicine, Durham, NC
Transplant patients treated with belatacept without depletional induction show high rates of costimulation blockade resistant rejection (CoBRR); this has been associated with CD57+ T cells.…2017 American Transplant Congress
The mTOR Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury.
Urology, Zhongshan Hospital, Fudan University, Shanghai, China
The mammalian target of rapamycin (mTOR) is a serine–threonine kinase that senses various environmental stimuli. The mTOR signal controls innate and adaptive immune response in…2017 American Transplant Congress
Inhibition of Multiple Nodes in the PI3K/Akt/mTOR Pathway Synergistically Suppresses Epstein-Barr Virus B Cell Lymphomas.
Division of Abdominal Transplantation, Stanford School of Medicine, Palo Alto, CA
Treating post-transplant lymphoproliferative disorders (PTLD) remains a clinical challenge due to adverse effects such as graft rejection. mTOR inhibitors, including rapamycin (RAPA), have shown both…2017 American Transplant Congress
Timing of Mesenchymal Stem Cell Infusions Affects Rejection Free and Overall Islet Allograft Survival.
We recently demonstrated that autologous, bone marrow-derived mesenchymal stem cells (MSC) promote allogeneic islet engraftment and survival in a streptozotocin induced, cynomolgus monkey model of…
American Transplant Congress abstracts